| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| talabostat | dipeptidyl peptidase 8 | NA | Clinical trial target | TTD , DGIDB | Neutropenia[MeSHID:D009503] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] Leukopenia[MeSHID:D007970] |
12.73 | phase 3 | inhibitor |
| talabostat | dipeptidyl peptidase 8 | NA | Clinical trial target | TTD , DGIDB | Neutropenia[MeSHID:D009503] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] Leukopenia[MeSHID:D007970] |
12.73 | phase 3 | unknown |
| talabostat | dipeptidyl peptidase 9 | NA | Clinical trial target | TTD , DGIDB | Neutropenia[MeSHID:D009503] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] Leukopenia[MeSHID:D007970] |
12.73 | phase 3 | unknown |
| talabostat | dipeptidyl peptidase 9 | NA | Clinical trial target | TTD , DGIDB | Neutropenia[MeSHID:D009503] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] Leukopenia[MeSHID:D007970] |
12.73 | phase 3 | inhibitor |
| talabostat | prolyl endopeptidase fap | NA | Clinical trial target | TTD , DGIDB | Neutropenia[MeSHID:D009503] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] Leukopenia[MeSHID:D007970] |
12.73 | phase 3 | unknown |
| click here to return to the previous page | ||||||||